Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Drug and ADC Payload Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TOP1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Target Enzyme (Recombinant Protein) | TOP1 WT & Mutant Recombinant Protein; high purity (>95%), endotoxin <1EU/μg, sequence verified; for DNA relaxation/cleavage assays. | View TOP1 Products |
| Gene Delivery (Lentivirus) | TOP1 Promise-ORF / Lentivirus; full-length ORF for stable cell lines expressing WT or mutant TOP1; resistance screening. | View TOP1 Products |
| Benchmark Tool (Antibody) | Anti-TOP1 Recombinant Antibody; positive control for Western Blot, IP, IHC; target engagement assays. | View TOP1 Products |
| Validator (siRNA) | TOP1 siRNA Set; for knockdown verification, synthetic lethality screening, specificity controls. | View TOP1 Products |
| Related Target A: HER2 | Primary surface target for TOP1-inhibitor ADCs (e.g., T-DXd). | View HER2 Products |
| Related Target B: TROP2 | Dominant epithelial target for SN-38/DXd conjugated ADCs; synergistic ADC payload delivery axis. | View TROP2 Products |
| Related Target C: PARP1 | Synthetic lethality partner; combination therapy node with TOP1 inhibition. | View PARP1 Products |
| Related Target D: TOP2A | Off-target liability counter-screen; essential selectivity homolog for TOP1 drug profiling. | View TOP2A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Enzymatic Assay Consistency & Cleavage-Complex Stabilization | High-purity (>95%) recombinant TOP1 (WT & Mutants) with native folding; ideal for DNA relaxation and cleavage assays. |
| Resistance Mutation Profiling | Human WT & Hotspot Mutant TOP1 proteins available (e.g., dbSNP:rs6029542, breast cancer somatic, CPT-resistant leukemia mutations); Sequence Verified >95% purity. |
| ADC Payload Mechanism Deconvolution | High-purity TOP1 for cleavage-complex stabilization assays; lentivirus for resistance modeling. |
| Selectivity vs TOP2A Counter-Screening | Homolog panel (TOP1 vs TOP2A) strictly verified by mass spec. |
| Lack of Standardization & Controls | Sequence-verified constructs, endotoxin-controlled, benchmark antibodies included. |
| False Positives | High-efficiency siRNA sets for specificity controls. |
Live TOP1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TOP1-targeted therapeutics is intensifying, with major players shifting focus from traditional small-molecule inhibitors to highly potent antibody-drug conjugates (ADCs) leveraging TOP1 inhibitor payloads. First-generation camptothecin derivatives established the target clinically, but the current wave—exemplified by DXd and SN-38 linker-payload technologies—has redefined efficacy in solid tumors. As these programs reach late-stage development and market expansion, the next wave of R&D is targeting optimized linker stability, enhanced bystander effects, acquired resistance mutations in TOP1, and synthetic lethal combinations with DDR pathways such as PARP. The integration of high-purity recombinant TOP1 reagents is critical for deconvoluting resistance mechanisms and enabling rational payload design.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC (TOP1 Payload) | Daiichi Sankyo, Gilead, AstraZeneca | Breast, Lung, Gastric, TROP2+ Solid Tumors | In vitro cleavage assay & cleavage-complex stabilization (Need high-purity WT & Mutant TOP1) |
| Small Molecule Inhibitor | Novartis, Servier, Pfizer, BMS | Colorectal, Ovarian, Small-Cell Lung Cancer | Cell viability screening & selectivity panel (Need lentivirus for overexpression, TOP2A counter-screen) |
| Bispecific ADC | Sichuan Kelun-Biotech, Merus | Solid Tumors | Dual-target pathway validation (Need Target + Related Antigens) |
| Combination Therapy | AstraZeneca, Merck, academic consortia | Refractory Solid Tumors | Synthetic lethality & rescue assay (Need PARP1 + TOP1 co-expression lentivirus) |
Key Mutations & Resistance Profiling in TOP1
Understanding TOP1 mutations is essential for drug resistance profiling. Key documented mutations include:
- dbSNP:rs6029542 (UniProt VAR_052592) – a population variant.
- Breast cancer somatic mutation (UniProt VAR_036555) – associated with tumorigenesis.
- CPT-resistant leukemia mutation (UniProt VAR_010666) – confers resistance to camptothecin derivatives.
TarMart provides recombinant TOP1 proteins covering these hotspot mutations, enabling functional assays, selectivity testing, and mechanism-of-action studies for next-generation inhibitors and ADCs.